AUSTIN GRANATOWICZ: Open Payments
NPI 1184240533 · SOUTH SIOUX CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,558 in 103 payments from 23 companies in 2025. Trend: 2023 $402 · 2024 $1,940 · 2025 $1,558
Food & beverage: $1,558
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $283 |
| ABBVIE INC. | 21 | $273 |
| PFIZER INC. | 11 | $163 |
| Novo Nordisk Inc | 9 | $161 |
| GlaxoSmithKline, LLC. | 18 | $143 |
| Astellas Pharma US Inc | 5 | $77 |
| E.R. Squibb & Sons, L.L.C. | 3 | $49 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| Verona Pharma, Inc. | 2 | $45 |
Products named: FARXIGA, VRAYLAR, Ozempic, NURTEC ODT, ELIQUIS, Veozah, QULIPTA, TRELEGY ELLIPTA.
Industry payments across NE — which companies pay providers there.
